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The V protein of the paramyxovirus Nipah virus (NiV) has been shown to antagonize the interferon
(IFN) response in human cells via sequestration of STAT1 and STAT2. This study describes a
mutant of the NiV V protein, referred to as V(AAHL), that is unable to antagonize IFN signalling and
demonstrates that a single amino acid substitution is responsible for its inactivity. The molecular
basis for this was identiﬁed as a failure to interact with STAT1 and STAT2. It was also shown
that NiV V, but not V(AAHL), was functional as an IFN antagonist in human, monkey, rabbit, dog,
horse, pig and bat cells, which suggests that the ability of NiV to block IFN signalling is not a major
constraint that prevents this virus from crossing species barriers.
In the last decade, zoonotic outbreaks of respiratory disease
and encephalitis affecting humans, horses and pigs in
Australia, Malaysia and Singapore have led to the isolation
of two novel paramyxoviruses, Hendra virus (HeV) and
Nipah virus (NiV) (Chua et al., 2000; Murray et al., 1995;
O’Sullivan et al., 1997). However, due to characteristic
differences from other paramyxoviruses they have been
assigned to a new genus, Henipavirus (Wang et al., 2000).
The natural hosts of both HeV and NiV are fruit bats
(suborder Megachiroptera) of the genus Pteropus (Chua
et al., 2002; Halpin et al., 2000). Neutralizing antibodies to
NiV have also been found in an insectivorous bat (suborder
Microchiroptera) (Yob et al., 2001). In the initial HeV and
NiV outbreaks, the viruses were transmitted from bats to
humans by way of intermediate animal hosts, horses and
pigs, respectively (Chua et al., 2000). More recent outbreaks
of NiV in Bangladesh and India have led to further human
deathsandmayhavebeenaresultofbothbat-to-humanand
human-to-human transmissions (Butler, 2004; Chadha
et al., 2006; Enserink, 2004; Hsu et al., 2004).
Similar to other paramyxoviruses, both henipaviruses have
the potential to express multiple proteins, P, V, W and C,
fromthePgenebyRNAeditingandalternativetranslational
initiation (reviewed by Lamb & Kolakofsky, 2001). The V
and/or C proteins of various paramyxoviruses have been
demonstrated to antagonize the interferon (IFN) system,
partoftheinnatecellularimmuneresponsetoviralinfection,
in several distinct ways (for recent reviews, see Horvath,
2004; Nagai & Kato, 2004; Stock et al., 2005). NiV and HeV
antagonize both IFN-a/b and IFN-c signalling via the
binding and sequestration of STAT1 and STAT2 in high-
molecular-mass complexes (Rodriguez et al., 2002, 2003). In
other paramyxoviruses, the highly conserved cysteine-rich C
terminus of the V protein is required to antagonize
IFN signalling, but although henipavirus V proteins share
this conserved C-terminal domain, it is dispensable for
the sequestration of STAT1 and STAT2 by these viruses
(Rodriguezetal.,2004;Shawetal.,2004).TheregionsofNiV
VthatinteractwithSTAT1andSTAT2havebeenmappedto
the N terminus of the protein, from residues 100 to 160 for
STAT1 binding and a larger region comprising residues
100–300 for STAT2 binding (Rodriguez & Horvath, 2004;
Rodriguez et al., 2004). A similar study by Shaw et al. (2004)
identiﬁed an overlapping area, residues 50–150, as sufﬁcient
for binding of STAT1 (Shaw et al., 2004). These regions are
alsopresentintheNiVPandWproteins,bothofwhichhave
been demonstrated to block IFN-a/b signalling and to bind
STAT1 (Rodriguez et al., 2002; Shaw et al., 2004). The P, V
and W proteins of NiV, as well as the C protein, which has a
sequence distinct from other P gene products as a result of
alternative translational initiation, also antagonize the IFN
response in chicken cells (Park et al., 2003).
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circumvent the IFN response in different species, we were
looking at the V protein of NiV. To this end, a cDNA
encoding the NiV P gene was isolated from a plaque-
puriﬁed NiV stock held at the Australian Animal Health
Laboratory in Geelong, Australia (named NiV-AAHL for
this study), which was derived from a human isolate. As the
V mRNA is produced by insertion of a non-templated G
residue into the P gene transcript at a conserved editing site,
we introduced an extra G residue into the cDNA by
overlapping PCR and cloned the open reading frame into
the mammalian expression vector pEF.plink2 (Didcock
et al., 1999). A c-myc epitope tag was fused to the N
terminusofNiVVtofacilitatedetectionoftheprotein.Very
surprisingly, given previously published work, IFN signal-
ling assays in Vero cells showed that NiV-AAHL V [referred
to as V(AAHL) hereafter] was unable to antagonize either
IFN-a/b (Fig. 1a) or IFN-c signalling (data not shown).
Sequence analysis of the V(AAHL) gene and comparison
with the V gene of the reference strain originally published
by the CDC group (GenBank accession no. NP_112023;
Chuaetal.,2000)andtermedV(CDC)inthisstudyrevealed
fournucleotidedifferences,twoofwhichresultedinchanges
in the amino acid sequence of the V protein at residues 125
and 280 (Fig. 1b, open boxes). The P sequence from which
V(AAHL)hadbeenderiveddifferedfromtheCDCsequence
in the same four nucleotides. As V(CDC) was shown by
Rodriguez et al. (2002) to block IFN signalling (Rodriguez
et al., 2002), we mutated residues 125 and 280 in V(AAHL)
to theequivalent residuesin V(CDC).The resulting protein,
termed V*(CDC), was able to antagonize both IFN-a/b and
IFN-c signalling in Vero cells (Fig. 1a and data not shown).
Subsequently, these two amino acid changes were intro-
duced into V(AAHL) individually, creating V(AAHL)-
E125G and V(AAHL)-D280N. As shown in Fig. 1(a), only
the mutant containing the E125G mutation was able to
block IFN-a/b signalling. V(AAHL)-E125G was also able to
antagonize IFN-c signalling (data not shown). These results
indicatedthatasingleaminoacidchangefromglutamicacid
(E) to glycine (G) at residue 125 enabled V(AAHL) to block
IFN signalling, suggesting that this residue plays a critical
role in IFN antagonism by NiV V. Subsequent immuno-
ﬂuorescenceexperimentsshowedthatconstructscontaining
the E125G mutation, V(AAHL)-E125G and V*(CDC),
prevented the nuclear translocation of STAT1 and STAT2
in response to IFN-a (Fig. 2a) and also the nuclear
translocation of STAT1 in response to IFN-c (not shown),
as previously demonstrated for V(CDC) (Rodriguez et al.,
2002), whilst V(AAHL) did not affect the distribution of
STATs. Furthermore, residue 125 lies within the proposed
STAT1- and STAT2-binding regions of NiV V (Rodriguez
et al., 2004; Shaw et al., 2004), suggesting that the inactivity
of V(AAHL) results from defective STAT binding. Indeed,
co-immune precipitation experiments showed that the
ability of V(AAHL) to bind STAT1 or STAT2 was
dramatically reduced, whereas introduction of the glycine
at residue 125 in V*(CDC) restored the binding capacity
(Fig. 2b). The G374A mutation also causes an amino acid
change in the sequence of the C protein. However, although
theCproteinhasbeenreportedtobeaweakIFNantagonist,
its mode of action is unknown (Park et al., 2003; Shaw et al.,
2004) and thus speculation about the possible inﬂuence of
such a mutation on the function of C cannot be made at
present.
NiV is able to replicate not only in bats, humans and pigs,
but also in a number of other species such as hamsters, cats,
dogs and horses (Hooper et al., 2001; Middleton et al., 2002;
Wong et al., 2003). We analysed the ability of NiV V to
Fig. 1. NiV V(AAHL) inhibitory activity is disrupted by a point
mutation. (a) Vero cells were transfected with expression vec-
tors for myc-tagged NiV V variants (as indicated) or empty
pEF.plink2 expression vector (Ctrl). Cells were also transfected
with an IFN-a/b-responsive luciferase reporter plasmid
[p(9–27ISRE)4tkD(”39)lucter] and a housekeeping-controlled
b-galactosidase reporter plasmid (pJATlacZ) (Didcock et al.,
1999). Cells were stimulated with 1?8610
4 IU IFN-a ml
”1
(Roferon-A; Roche Diagnostics) (+) or left untreated (”), and
4–6 h later were lysed and assayed for luciferase and b-galac-
tosidase activity. Luciferase values were normalized to b-galac-
tosidase values and the results are shown as means±SD
obtained from ﬁve independent transfections. Means of induc-
tion factors (induced/uninduced activity) are indicated below
the graph. (b) Schematic representation of V(CDC) with
STAT1- and STAT2-binding regions. Shaded areas indicate
(from left to right) the STAT1-binding region, the nuclear export
signal (NES), essential residues interacting with STAT2 (*) and
the conserved C-terminal domain (C-term). Numbers above the
bar represent amino acid positions. Nucleotide and amino acid
differences in V(AAHL) are indicated in open boxes. The
P206L mutation (see Fig. 3) is indicated in the ﬁlled box.
Upper case is used for amino acid residues and lower case for
nucleotides.
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including Tb1 Lu lung epithelial cells from Tadarida
brasiliensis (ECACC 90020805), which were of particular
interest asthe bat population of Southeast Asia is thought to
be the reservoir of NiV. [It should be noted that T.
brasiliensis is not among the bat species identiﬁed as the
natural host of NiV. However, in addition to four species of
fruitbat,antibodiesagainstNiVhavealsobeenfoundintwo
insectivorous bats, which are more closely related to T.
brasiliensis (Field et al., 2001; Wacharapluesadee et al., 2005;
Yob et al., 2001).]
The results from a panel of assays done in cell lines from
different species are summarized in Fig. 3(a). V*(CDC) was
able to inhibit IFN-a signalling in all species tested, i.e. cells
from human, monkey, pig, dog, rabbit, horse and bat. The
mutantV(AAHL)wasinactiveinallspeciestestedexceptthe
bat cells, in which it retained some residual activity. A
detailed representation of the results obtained in bat Tb1 Lu
cells is given in Fig. 3(b). Due to the lack of appropriate
tools, such as the sequences of the STAT genes from bat or
effective antibodies against bat STAT proteins, we cannot at
present provide an experimental explanation for this
phenomenon. It might, however, point to a difference in
the sequence of bat STAT proteins compared with the other
species investigated here.
Single amino acid substitutions affecting IFN sensitivity
have been observed in other paramyxoviruses and could
reﬂect the ability of these viruses to cross species barriers
(Chatziandreou et al., 2002; Garcin et al., 2002; Young et al.,
2001). It was therefore of considerable importance to know
whether the G125E mutant was a natural variant that might
play a role inthe species-speciﬁcinhibitionof IFNsignalling
or whether it had been generated during cloning of the
V(AAHL) gene. We managed to obtain an earlier passage of
the original human isolate of NiV(AAHL), as well as the
plaque-puriﬁed stock that had been used to generate the
Fig. 2. NiV V(AAHL) does not interact with STAT1 or STAT2. (a) Immunoﬂuorescence. 2fTGH cells were transfected with
myc-tagged V(AAHL), V*(CDC) or V(AAHL)-E125G expression constructs and stimulated for 70 min with 1?8610
4 IU IFN-a
ml
”1 (Roferon-A; Roche Diagnostics). Cells were ﬁxed and stained with antibodies against the myc tag (green ﬂuorescence)
and against either STAT1 (red ﬂuorescence, left panels) or STAT2 (red ﬂuorescence, right panels) as indicated. (b) Co-
immunoprecipitation. 293 cells were transfected with expression constructs encoding STAT1 and STAT2 and either myc-
tagged V(AAHL) or V*(CDC). Cells were lysed at 48 h post-transfection and complexes containing the V and STAT proteins
were precipitated from the lysates using antibodies against either STAT2 or the myc tag, as indicated above each panel. The
precipitates were analysed by Western blotting with antibodies detecting either STAT1 and the myc tag or STAT2, as
indicated below the panels. The lower right panel conﬁrms efﬁcient precipitation with the anti-STAT2 antibody in all three
lysates. HC, Antibody heavy chain; LC, antibody light chain.
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ampliﬁed the relevant region of the V genes that contained
the position in question (positions 8–569, mRNA sense) by
RT-PCR. The sequences obtained from both products had a
guanine at position 374, which corresponds to a glycine at
position125oftheaminoacidchain,andwerethusidentical
to the sequence published for V(CDC). The most likely
explanation for this discrepancy therefore appears to be that
V(AAHL) represents a PCR artefact that arose during
cloning of the expression plasmid. However, given the
observation that the G125E mutation did not completely
disrupt the function of the V protein in bat cells, we cannot
rule out the possibility that, rather than being coincidental,
the mutation might have been present in a small population
of virus particles in the original stock. Whatever its origin,
the results presented here demonstrate that a single amino
acid in the STAT1/2-binding region of NiV V is critical for
its ability to bind and prevent the relocalization of STATs in
response to IFN stimulation. These ﬁndings underscore the
importance of the N-terminal region of V for interaction
with STATs (Rodriguez et al., 2004; Shaw et al., 2004).
Recently, a number of sequences from NiV isolated from
humans and pigs, as well as a single bat isolate, have been
added to the database (AbuBakar et al., 2004; Chan et al.,
2001; Chua et al., 2000, 2002; Harcourt et al., 2005). There
are 0–4 aa changes between the V sequences of the different
NiV isolates from Malaysia. The isolate from Bangladesh
(GenBank accession no. AAY43918; Harcourt et al., 2005)
shows considerable variation (up to 53 aa changes, i.e.
~10%,throughouttheVproteinsequence)comparedwith
theMalayanisolates.However,inalloftheNiVVsequences,
including the bat isolate, and also in the V sequence of the
more distantly related HeV, the glycine at position 125 is
conserved, in spite of the overall variability of this sequence.
Sequence comparison also revealed a single amino acid
difference, at position 206 (indicated as a ﬁlled box in
Fig. 1b), between the human isolate from Malaysia (the
CDC isolate) and the Malaysian bat isolate (GenBank
accession no. AAM13407; Chua et al., 2002). Although this
mutation (P206L) does not lie within the immediate STAT-
binding regions, nor within any other identiﬁed motif, the
substitution of a proline residue could potentially have a
dramaticeffectonthefunctionalityoftheprotein.However,
when weintroducedthe P206L mutation into V*(CDC),the
resulting proteinV(CDC-P206L)inhibitedIFNsignalling as
efﬁciently as V*(CDC) in human as well as in bat cells
(Fig. 3c).
The ability to circumvent the IFN response is one of many
factors that can inﬂuence the host range of a virus. In this
study, the V protein of wild-type NiV proved to be
functional as an antagonist of IFN signalling in cells from
seven different species. Although these experiments only
considered the functionality of V in vitro, reports on
experimental and ﬁeld infections by other groups conﬁrm
that NiV is able to infect and replicate in animals from a
broad range of species. Given these observations, the ability
of NiV to block IFN signalling does not appear to be a major
constraint that prevents this virus from crossing species
barriers.
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Fig. 3. Inhibition of IFN signalling in cells of different species.
(a) Summary of signalling results. IFN-a/b signalling assays
were carried out as described. +, Inhibition of signalling; ”,
failure to inhibit signalling. Results were classiﬁed as positive
(+) when the induction factor was reduced to 30% or lower
compared with the negative control and the value of the stimu-
lated sample was reduced to 25% or lower compared with the
negative control. (b) Details of the results for Tb1 Lu cells
given in (a). Instead of commercial IFN-a, these cells were sti-
mulated with puriﬁed and UV-inactivated supernatant from Tb1
Lu cells infected with rSV5VDC (He et al., 2002), a strong
inducer of IFN production. Results are shown as means±SD
from six independent transfections. Means of induction factors
(induced/uninduced activity) are indicated below the graph. (c)
Comparison of inhibition of IFN signalling by NiV V(CDC)-
P206L in Hep2 and Tb1 Lu cells. Results are shown as
means±SD from six (Hep2) or three (Tb1 Lu) independent
transfections. Means of induction factors (induced/uninduced
activity) are indicated below the graph.
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